natgillin/translations-raw huggingface dataset:
The other ingredients are: - tablet core: hydroxypropylcellulose, microcrystalline cellulose, lactose monohydrate, crospovidone, magnesium stearate - film-coating: hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172), iron oxide red (E172)
magnezijev stearat - Filmska obloga: hipromeloza, titanov dioksid (E171), triacetin, rumeni železov oksid (E172),
Some people may have more gout attacks (sudden or severe pain and swelling in a joint, also called a gout flare) when they start using Duzallo and during the first weeks or months of treatment.
Nekateri bolniki imajo lahko po začetku uporabe zdravila Duzallo in v prvih tednih ali mesecih zdravljenja več napadov protina (nenadna ali huda bolečina ali otekanje sklepov, kar tudi imenujemo ponovni zagon protina).
The choice of the dose strength of Duzallo depends on the allopurinol dose taken as individual tablet(s).
Izbira jakosti odmerka zdravila Duzallo je odvisna od odmerka alopurinola, ki ga bolnik jemlje kot samostojno tableto.
They may be pruritic, maculopapular, sometimes scaly, sometimes purpuric and rarely exfoliative, such as SJS/TEN.
Lahko so srbeče, makulopapulozne, občasno luskaste ali kot purpura in redko kot eksfoliativni izpuščaj, na primer pri Stevens-Johnsonovem sindromu in toksični epidermalni nekrolizi (SJS/TEN).
Rare cases of hypersensitivity (photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria) have been reported with lesinurad during the clinical programme.
V kliničnem programu so bili med uporabo lesinurada opisani redki primeri preobčutljivosti (fotodermatoza, fotosenzitivna reakcija, alergijski dermatitis, srbenje in urtikarija).
In each of the studies, a greater proportion of patients treated with lesinurad 200 mg in combination with allopurinol compared with placebo in combination with allopurinol achieved a serum uric acid level of less than 5 mg/dL by Month 6 (CLEAR1: 29% versus 10%; CLEAR2: 35% versus 5%).
V obeh študijah je koncentracijo sečne kisline v serumu manj kot 5 mg/dl do 6. meseca dosegel večji delež bolnikov, ki so dobivali kombinacijo 200 mg lesinurada in alopurinola, kot tistih, ki so dobivali kombinacijo placeba in alopurinola (CLEAR1: 29% v primerjavi z 10%, CLEAR2: 35% v primerjavi s 5%).
This leaflet was last revised in
Navodilo je bilo nazadnjerevidirano dne
Male infertility, erectile dysfunction, gynaecomastia
Motnje reprodukcije in dojk neplodnost pri moških, erektilna disfunkcija, ginekomastija
What Duzallo contains
Kaj vsebuje zdravilo Duzallo
Allopurinol and oxypurinol clearance is greatly reduced in patients with poor renal function resulting in higher plasma levels in chronic therapy.
Pri bolnikih z okvarjenim delovanjem ledvic sta očistka alopurinola in oksipurinola močno zmanjšana, kar ob dolgotrajnem zdravljenju povzroči višje plazemske koncentracije.
The rates of gout flare requiring treatment were low and comparable to placebo in the last 6 months of the randomised trials (after gout flare prophylaxis was discontinued) with median scores of zero.
Klinični izidi - napadi protina, ki so zahtevali zdravljenje Delež napadov protina, ki so zahtevali zdravljenje, je bil v zadnjih 6 mesecih randomiziranih preskušanj (po prenehanju uporabe profilakse napadov) majhen in podoben kot pri placebu; mediani seštevek je bil nič.
- you have thyroid disorders
- če imate bolezni ščitnice
Hypersensitivity reactions may present themselves as fever, skin reactions, chills and arthralgia.
Preobčutljivostne reakcije se lahko kažejo kot zvišana telesna temperatura, spremembe na koži, mrazenje ali bolečine v sklepih.
Agranulocytosis*, aplastic anaemia*, thrombocytopenia*
Bolezni krvi in limfatičnega sistema agranulocitoza*, aplastična anemija*, trombocitopenija*
Hypersensitivity*
Bolezni imunskega sistema preobčutljivost**
In both studies, significantly more patients treated with lesinurad 200 mg in combination with allopurinol ≥ 300 mg/day (≥ 200 mg/day in subjects with moderate renal impairment) achieved the target serum uric acid level of less than 6 mg/dL by Month 6 and by Month 12 compared with patients receiving placebo in combination with allopurinol (see Table 3).
V obeh študijah je ciljno koncentracijo sečne kisline v serumu manj kot 6 mg/dl do 6. in do 12. meseca doseglo značilno več bolnikov, ki so prejemali kombinacijo 200 mg lesinurada in alopurinola ≥ 300 mg/dan (≥ 200 mg/dan pri bolnikih z zmerno okvaro ledvic) kot bolnikov, ki so prejemali kombinacijo placeba in alopurinola (glejte preglednico 3).
No increased incidences for adjudicated Major Adverse Cardiovascular Events (MACE) were observed in the randomised, double-blind, placebo-controlled combination therapy clinical studies (CLEAR1 and CLEAR2) (see section 5.1).
V randomiziranih, dvojno slepih, s placebom nadzorovanih kliničnih študijah kombiniranega zdravljenja (CLEAR1 in CLEAR2) niso poročali o povečani pojavnosti bolnikov s prisojenimi večjimi srčno-žilnimi neželenimi učinki (MACE - Major Adverse Cardiovascular Events) (glejte poglavje 5.1).
Very rare - may affect up to 1 in 10,000 people - chest pain, slow heartbeat, high blood pressure or a slow pulse, - vomiting blood (recurrent hematemesis), presence of excess fat in the stool (steatorrhea), - inflammation of the mucous membranes of the mouth (stomatitis), changed stool frequency (changed bowel motions), - hair loss or discoloration, - abnormal glucose metabolism (diabetes; your doctor may wish to measure the level of sugar in your blood to check if this is happening), - high levels of cholesterol in your blood (hyperlipidaemia), - depression, - coma, - weakness, numbness, unsteadiness on your feet, unable to move muscles (paralysis) or loss of consciousness, - not able to control muscle movements (ataxia), - sensation of tingling, tickling, pricking or burning of skin (paraesthesia), - headache, dizziness, drowsiness or disturbance of your vision, - cloudiness of the eye (cataract), - a change in taste, - blood in your urine (haematuria), - male infertility or erectile dysfunction, - enlargement of the breasts, in men as well as in women, - build-up of fluid leading to swelling (oedema) particularly of your ankles, - muscle aches, - painful skin boil, - damage to the nerves which can cause numbness, pain and weakness.
Zelo redki - pojavijo se lahko pri največ 1 od 10.000 bolnikov - bolečina v prsih, upočasnjen srčni utrip, visok krvni tlak in upočasnjen pulz, - bruhanje krvi (ponavljajoča se hematemeza), prisotnost čezmerne maščobe v blatu (steatoreja), - vnetje ustne sluznice (stomatitis), spremenjena pogostnost odvajanja blata, - plešavost in obarvanje las, - nenormalna presnova glukoze (sladkorna bolezen; zdravnik vam bo morda izmeril raven sladkorja v krvi, da bo preveril, če se to dogaja pri vas), - visoka raven holesterola v krvi (hiperlipidemija), - depresija, - koma, - šibkost, odrevenelost, nestabilnost na nogah, občutek nezmožnosti premikanja mišic (paraliza)
Primary end-point in patients with renal impairment Consistent with the overall population, the proportion of patients with mild to moderate renal impairment (eCrCL 30-89 mL/min) who achieved target serum uric acid levels at Month 6 was 56% for lesinurad 200 mg versus 29% for placebo when added to allopurinol at doses ranging from 200 mg to 900 mg.
Tako kot v celotni populaciji je bil delež bolnikov z blago do zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 89 ml/min), ki so 6. mesec dosegli ciljno koncentracijo sečne kisline v serumu, 56% z 200 mg lesinurada in 29% s placebom po dodatku alopurinola v odmerkih 200 mg do 900 mg.
Testing for the target serum uric acid level can be performed after 4 weeks to consider treatment adjustment to target serum uric acid level.Gout flare prophylaxis needs to be considered (see section 4.4).
Preverjanje ciljne koncentracije sečne kisline v serumu lahko opravimo po 4 tednih, da po potrebi prilagodimo zdravljenje do ciljne koncentracije sečne kisline v serumu.
OUTER CARTON for 10, 30 and 100 film-coated tablets
ŠKATLA za 10, 30 in 100 filmsko obloženih tablet
The signs may include: Uncommon - may affect up to 1 in 100 people - pain in your side (below your ribs and above your hipbone), - feeling sick (nausea), - being sick (vomiting), - changes in urination or difficulty urinating, - feeling tired or unwell or loss of appetite.
Občasni - pojavijo se lahko pri največ 1 od 100 bolnikov - bolečine v ledvenem predelu (pod rebri in nad kolčnico), - slabost v želodcu (siljenje na bruhanje), - bruhanje, - spremembe pri odvajanju vode ali težave z odvajanjem vode, - utrujenost, slabo počutje ali izgubo apetita.
Do not stop taking Duzallo without talking to your doctor first even if you feel better.
Tudi če se počutite bolje, ne prenehajte jemati zdravila Duzallo, če vam tega ne svetuje zdravnik.
Adverse reactions related to renal function can occur after initiating Duzallo (see section 4.8)
Po uvedbi zdravila Duzallo se lahko pojavijo neželeni učinki povezani z delovanjem ledvic (glejte poglavje 4.8).
Inhibition of the metabolism of theophylline by allopurinol has been reported.
Poročali so, da alopurinol zavira presnovo teofilina.
- acetylsalicylic acid - to relieve fever and pain at doses above 325 mg per day - medicines to treat high blood pressure such as ACE inhibitors, water tablets (diuretics medicines that increase the passing of urine) and calcium channel blockers e.g. amlodipine - medicines to treat high cholesterol levels, e.g. simvastatin - fluconazole - to treat fungal infections - amiodarone - to treat heart rhythm problems - valproic acid, valpromide, phenytoin or carbamazepine - to prevent fits (seizures), mood disorders and prevent migraines - bupropion - for treating depression or to help stop smoking - sildenafil - to treat erectile problems in men - contraceptives - used to prevent pregnancy, including oral contraception (such as ‘the pill'), injections, patches and implants - coumarin anticoagulants - to prevent and treat blood clots - antibiotics like ampicillin or amoxicillin
(konvulzij), motenj razpoloženja in preprečevanje migrene; - bupropion - za zdravljenje depresije ali pomoč pri prenehanju kajenja; - sildenafil - za zdravljenje motenj erekcije; - kontraceptivi - uporabljajo se za preprečevanje nosečnosti in vključujejo peroralne kontraceptive (kontracepcijske tabletke), kontracepcijske injekcije, obliže in vsadke - kumarinski antikoagulanti - za preprečevanje nastanka krvnih strdkov in njihovega zdravljenja; - antibiotiki, kot sta ampicilin in amoksicilin; - zdravila za zdravljenje okužbe z virusom HIV (AIDS), npr. didanozin, efavirenz;
Diabetes mellitus, hyperlipidaemia
Presnovne in prehranske motnje dehidracija sladkorna bolezen, hiperlipidemija
Musculoskeletal and connective tissue disorders
Bolezni mišično-skeletn ega sistema in vezivnega tkiva mialgija
In the pivotal clinical trials, a greater proportion of patients using lipid lowering or anti-hypertensive medicinal products that were CYP3A substrates required concomitant medicinal product change when treated with lesinurad 200 mg in combination with a xanthine oxidase inhibitor, compared with patients treated with placebo in combination with a xanthine oxidase inhibitor (35% versus 28%, respectively).
Zamenjavo sočasnih zdravil je potreboval večji delež bolnikov, ki so obenem jemali kombinacijo lesinurada 200 mg in zaviralca ksantin-oksidaze, kot tistih, ki so jemali kombinacijo placeba in zaviralca ksantin-oksidaze (35% prvih in 28% drugih).
Duzallo is not recommended during breastfeeding.
Zdravilu Duzallo se je med dojenjem bolje izogibati.
with lesinurad in combination with allopurinol - Pooled data from CLEAR1 and CLEAR2 studies
Preglednica 3 Delež bolnikov, ki so dosegli ciljno koncentracijo sečne kisline v serumu (< 6 mg/dl) z lesinuradom v kombinaciji z alopurinolom - kumulativni podatki študij CLEAR1 in CLEAR2
Hypromellose Titanium dioxide (E171) Triacetin
Obloga tablete hipromeloza titanov dioksid (E171) triacetin rumeni železov oksid (E172) rdeči železov oksid (E172)
In the randomised, double-blind, placebo-controlled combination therapy clinical studies, the incidences of patients with adjudicated Major Adverse Cardiovascular Events (MACE; cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) per 100 patient-years of exposure were 0.60 (95% confidence interval (C.I.)
V randomiziranih, dvojno slepih, s placebom nadzorovanih kliničnih študijah kombiniranega zdravljenja je bila pojavnost bolnikov s prisojenimi večjimi srčno-žilnimi neželenimi učinki (MACEMajor Adverse Cardiovascular Events: srčno-žilna smrt, miokardni infarkt brez smrtnega izida ali možganska kap brez smrtnega izida) na 100 bolnikov- let izpostavljenosti 0,60 (95% interval zaupanja (IZ): 0,15; 2,41) s placebom in 0,61 (95% IZ 0,15; 2,43) z 200 mg lesinurada, kadar sta bila uporabljena skupaj z alopurinolom (CLEAR1 in CLEAR2).
Gout flares may occur after initiation of therapy with Duzallo.
Po uvedbi zdravila Duzallo se lahko pojavijo napadi protina.
azathioprine - vidarabine, used to treat herpes or chickenpox - cytostatics (e.g. cyclophosphamide, doxorubicin, bleomycin, procarbazine, alkylating agents, mercaptopurine), used to treat cancer or rheumatic diseases - aluminium hydroxide, used to treat heartburn and acid indigestion (you should leave an interval of at least 3 hours between taking the two medicines)
merkaptopurin), ki se uporabljajo za zdravljenje raka in revmatskih obolenj; - aluminijev hidroksid, ki ga uporabljamo pri zgagi in refluksu (med jemanjem enega in drugega zdravila morajo preteči vsaj 3 ure)
Lesinurad 200 mg vs. placebo
Lesinurad 200 mg v primerjavi s placebom
Kidney problems
Težave z ledvicami
Time from Baseline in Months placebo (4.2%), resulting in discontinuation of treatment in 1.0% for both treatment setups (see section
O neželenih učinkih v povezavi z ledvicami so poročali pri bolnikih, ki so prejemali 200 mg lesinurada (4,9%), v primerjavi z bolniki, ki so prejemali placebo (4,2%); ti neželeni učinki so povzročili prenehanje zdravljenja pri 1,0% bolnikov iz obeh terapevtskih skupin (glejte poglavje 4.4).
Over time, your gout attacks will occur less often if you keep taking Duzallo as advised by your doctor.
Če boste zdravilo Duzallo še naprej jemali, kot vam je svetoval zdravnik, bodo napadi protina sčasoma postali manj pogosti.
Gastrooesophageal reflux disease
Žilne bolezni hipertenzija
Uncommon - may affect up to 1 in 100 people - kidney stones, - kidney stop working properly, - skin reactions, including redness, itchy skin, lumpy rash (hives) and skin rash on exposure to sunshine, - dehydration (loss of too much fluid from your body), - feeling sick (nausea) or being sick (vomiting), - diarrhoea, - abnormal liver tests.
- ledvični kamni, - slabše delovanje ledvic, - kožne reakcije, vključno s pordelostjo, srbenjem, dvignjenim izpuščajem (koprivnico) in izpuščajem na koži po izpostavljenosti soncu, - dehidracija (prekomerna izguba tekočine iz telesa), - slabost v želodcu (siljenje na bruhanje) ali bruhanje, - driska, - nenormalni jetrni testi,
CYP2C9 poor metabolisers
Slabi presnavljalci s CYP2C9
Recurrent haematemesis, steatorrhoea, stomatitis, changed stool frequency
Bolezni prebavil gastroezofagea lna refluksna bolezen navzea, bruhanje in driska ponavljajoča se hematemeza, steatoreja, stomatitis, spremenjena pogostnost odvajanja blata
Duzallo 300 mg/200 mg film-coated tablets
Duzallo 300 mg/200 mg filmsko obložene tablete
Duzallo 200 mg/200 mg film-coated tablets
Duzallo 200 mg/200 mg filmsko obložene tablete
What Duzallo looks like and contents of the pack Duzallo 200 mg/200 mg film-coated tablets are pale pink oblong tablets and engraved with “LES200” and “ALO200” on one side.
Duzallo 200 mg/200 mg filmsko obložene tablete so bledo rožnate, podolgovate tablete in imajo na eni strani vgravirana napisa »LES200« in »ALO200«.
Renal failure***, renal impairment, nephrolithiasis
Bolezni sečil odpoved ledvic***, okvara ledvic, nefrolitiaza urolitiaza hematurija, azotemija
Duzallo should be interrupted if serum creatinine is elevated to more than 2 times the pre-treatment value or in case of an absolute serum creatinine value greater than 4.0 mg/dL.
Uporabo zdravila Duzallo je treba prekiniti, če se kreatinin v serumu zviša na več kot 2-kratno vrednost, kot je bila pred zdravljenjem, prav tako tudi v primeru absolutne vrednosti kreatinina v serumu nad 4,0 mg/dl. Zdravljenje je treba prekiniti pri bolnikih s simptomi, ki lahko kažejo na akutno urično nefropatijo: npr. z bolečinami v ledvenem predelu, navzeo ali bruhanjem; v tem primeru je treba takoj izmeriti kreatinin v serumu.
In two 12-month placebo-controlled trials of lesinurad in combination with allopurinol versus allopurinol alone (placebo), serum creatinine elevations between 1.5-fold and 2-fold over baseline occurred in 4.4% of patients on lesinurad 200 mg and 2.2% on placebo; serum creatinine elevations 2fold or greater over baseline occurred in 1.5% of patients on lesinurad 200 mg and 0% on placebo.
V teh preskušanjih se je zvišanje kreatinina v serumu, ki je bilo od 1,5- do 2-kratnik izhodiščnega, pojavilo pri 4,4% bolnikov, ki so prejemali 200 mg lesinurada, in pri 2,2% bolnikov, ki so prejemali placebo.
Oedema, general malaise, asthaenia
Splošne težave in spremembe na mestu aplikacije edem, splošno slabo počutje, astenija
Duzallo does not need to be discontinued because of a gout flare.
Zaradi napada protina zdravila Duzallo ni treba prenehati uporabljati.
What Duzallo looks like and contents of the pack Duzallo 300 mg/200 mg film-coated tablets are orange and slightly brownish oblong tablets and engraved with “LES200” and “ALO300” on one side.
Duzallo 300 mg/200 mg filmsko obložene tablete so bledo rožnate, podolgovate tablete in imajo na eni strani vgravirana napisa »LES200« in »ALO300«.
Rash and skin symptoms
Izpuščaj in spremembe na koži
Each Duzallo 300 mg / 200 mg film-coated tablet contains 300 mg of allopurinol and 200 mg of lesinurad.
Ena filmsko obložena tableta zdravila Duzallo 300 mg/200 mg vsebuje 200 mg alopurinola in 200 mg lesinurada.
Each Duzallo 200 mg / 200 mg film-coated tablet contains 200 mg of allopurinol and 200 mg of lesinurad.
Ena filmsko obložena tableta zdravila Duzallo 200 mg/200 mg vsebuje 200 mg alopurinola in 200 mg lesinurada.
Duzallo contains lactose
Zdravilo Duzallo vsebuje laktozo
Pale pink oblong film-coated tablets with 7 x 17 mm in size.
Bledo rožnate, podolgovate filmsko obložene tablete velikosti 7 x 17 mm. Filmsko obložene tablete imajo na eni strani vgravirana napisa »LES200« in »ALO200«.
Timepoint
Čas
Reproductive system and breast disorders
Infekcijske in parazitske bolezni gripa furunkel
Orange and slightly brownish oblong film-coated tablets with 8 x 19 mm in size.
Oranžne in rahlo rjavkaste podolgovate filmsko obložene tablete velikosti 8 x 19 mm. Filmsko obložene tablete imajo na eni strani vgravirana napisa »LES200« in »ALO300«.
Fertility
Citostatiki
Each film-coated tablet contains 300 mg allopurinol and 200 mg lesinurad
Ena filmsko obložena tableta vsebuje 300 mg alopurinola in 200 mg lesinurada
Consistent serum uric acid lowering was observed in patients who were receiving thiazide diuretics in the placebo-controlled clinical studies in combination with allopurinol.
V kliničnih študijah kombinacije z alopurinolom, nadzorovanih s placebom, so opažali dosledno znižanje sečne kisline pri bolnikih, ki so jemali tiazidne diuretike.
Duzallo 300 mg / 200 mg film-coated tablets allopurinol/lesinurad
Duzallo 300 mg/200 mg filmsko obložene tablete alopurinol/lesinurad
Each film-coated tablet contains 200 mg allopurinol and 200 mg lesinurad
Ena filmsko obložena tableta vsebuje 200 mg alopurinola in 200 mg lesinurada
Duzallo 200 mg / 200 mg film-coated tablets allopurinol/lesinurad
Duzallo 200 mg/200 mg filmsko obložene tablete alopurinol/lesinurad
Lesinurad undergoes oxidative metabolism mainly via cytochrome P450 (CYP) 2C9 to intermediate metabolite M3c (not detected in vivo) and is subsequently metabolised by microsomal epoxide hydrolase (mEH) to metabolite M4; there is minimal contribution from CYP1A1, CYP2C19, and CYP3A to the metabolism of lesinurad.
Lesinurad se presnovi z oksidativno presnovo, predvsem s citokromom P450 (CYP) 2C9, v vmesni presnovek M3c (in vivo ga niso odkrili).
Impaired liver function tests
Bolezni jeter, žolčnika in žolčevodov moteni testi delovanja jeter hepatitis
Monitor for decreased efficacy when Duzallo is co-administered with a CYP2C9 inducer.
Če se uporablja zdravilo Duzallo sočasno z induktorjem CYP2C9, je bolnika treba spremljati glede zmanjšane učinkovitosti.
A possible interaction should be taken into account when a patient on oral anticoagulants is given Duzallo.
Če prejme bolnik na peroralnih antikoagulantih zdravilo Duzallo, moramo upoštevati možnost medsebojnega delovanja.
Each film-coated tablet contains 200 mg of allopurinol and 200 mg of lesinurad.
Ena filmsko obložena tableta vsebuje 200 mg alopurinola in 200 mg lesinurada.
Each film-coated tablet contains 300 mg of allopurinol and 200 mg of lesinurad.
Ena filmsko obložena tableta vsebuje 300 mg alopurinola in 200 mg lesinurada.
The active substances are allopurinol and lesinurad.
Učinkovini sta alopurinol in lesinurad.
Impaction of uric acid renal stones
Zagozditev ledvičnih kamnov iz sečne kisline
This summary was last updated in November 2013.
Povzetek je bil nazadnje posodobljen novembra 2013.
Any contaminated clothes should be removed.
Vsa kontaminirana oblačila je treba odstraniti.
A number of laboratory studies and field trials in various countries were performed.
Izvedene so bile številne laboratorijske študije in terenski preskusi v različnih državah.
The European Commission granted a marketing authorisation valid throughout the European Union, for Zolvix on 4 November 2009.
Evropska komisija je dovoljenje za promet z zdravilom Zolvix, veljavno po vsej Evropski uniji, odobrila dne 4. novembra 2009.
This causes paralysis and death of the worms.
To povzroči paralizo in odmrtje glist.
Users who are administering this medicine to sheep should wear protective gloves.
Osebe, ki dajejo ovcam zdravilo, morajo nositi zaščitne rokavice.
Two main studies were carried out, one in Europe and one in New Zealand, in sheep suffering from a range of nematode infections.
Opravljeni sta bili dve glavni študiji, ena v Evropi in ena na Novi Zelandiji, pri ovcah s številnimi okužbami z glistami.
Other information about Zolvix:
Druge informacije o zdravilu Zolvix:
The effectiveness of Zolvix has not been established in sheep weighing less than 10 kg and safety has not been established in sheep weighing less than 10 kg or under two weeks of age.
Učinkovitost zdravila Zolvix ni bila dokazana pri ovcah, ki tehtajo manj kot 10 kg, njegova varnost pa ni bila dokazana pri ovcah, ki tehtajo manj kot 10 kg ali so stare manj kot dva tedna.
Zolvix is available as an oral solution (25 mg/ml).
Na voljo je kot peroralna raztopina (25 mg/ml).
Zolvix is given as a single dose of 2.5 mg per kilogram bodyweight.
Zdravilo Zolvix se daje v enkratnem odmerku 2,5 mg na kilogram telesne mase.
The withdrawal period for sheep for meat and offal is seven days.
Obdobje karence pri ovcah za meso in drobovino je sedem dni.
The oral solution is given directly on the back of the tongue.
Peroralna raztopina se daje neposredno na koren jezika.
To help delay the development of resistance, users are advised to check the success of the treatment by examining the sheep's clinical appearance, or by testing whether any parasite eggs can be found in the faeces.
Za podaljšanje časa do razvoja odpornosti se uporabnikom priporoča, da preverijo uspešnost zdravljenja s pregledovanjem kliničnih znakov ovc ali s preverjanjem, če so v iztrebkih prisotna jajčeca zajedavcev.
Zolvix is used for the treatment and control of worm infections of the gut and associated diseases in sheep.
Zdravilo Zolvix se uporablja za zdravljenje in nadzor črevesnih zajedavskih okužb in z njimi povezanih bolezni pri ovcah.
What benefit has Zolvix shown during the studies?
Kakšne koristi je zdravilo Zolvix izkazalo med študijami?
The amount to use is calculated based on the weight of the sheep.
Odmerek se izračuna na podlagi telesne mase ovce.